Alterity Therapeutics (ASX:ATH) has announced that its Phase 2 trial of ATH434 for treating patients with Multiple System Atrophy is now open for enrollment in Italy.
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 Australian Biotech
Latest Video
New Stories
-
Former Medicines NZ chair says the time for talk on Pharmac is over
December 5, 2023 - - Latest News -
Ex-TGA head John Skerritt appointed to Medicines Australia board
December 5, 2023 - - BioPharma -
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 - - Australian Biotech -
National Pharmacies opens its first 24-7 pharmacy under South Australian initiative
December 4, 2023 - - Latest News -
PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
December 4, 2023 - - Australian Biotech -
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
December 4, 2023 - - Australian Biotech -
Korean regulator approves Amplia Therapeutics' pancreatic cancer trial
December 4, 2023 - - Australian Biotech